FDA.reportPublic FDA data

RIFAXIMIN

Substance profile for UNII L36O5T016N, enriched with FDA NDC listings, DailyMed labels, legacy aliases, and open chemistry identifiers.

Chemical structure for RIFAXIMIN
Structure render from PubChem CID 6436173

Substance Identity#

UNII
L36O5T016N
Preferred term
RIFAXIMIN
Registry number
80621-81-4
Ingredient type
INGREDIENT SUBSTANCE
Molecular formula
C43H51N3O11
Chemical structure for RIFAXIMIN
Structure render from PubChem CID 6436173

Chemical And Database Identifiers#

InChIKey
NZCRJKRKKOLAOJ-XRCRFVBUSA-N
SMILES
CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C4=C5N=C6C=C(C)C=CN6C5=C(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C4C(O)=C3C
RxCUI
35619
PubChem
6436173
NCIt
C61926
INN ID
5244

Open Chemistry Sources#

Source, Identifier, Link table
SourceIdentifierLink
PubChem Compound6436173pubchem.ncbi.nlm.nih.gov/compound/6436173
PubChem InChIKey SearchNZCRJKRKKOLAOJ-XRCRFVBUSA-Npubchem.ncbi.nlm.nih.gov/#query=NZCRJKRKKOLAOJ-XRCRFVBUSA-N
RxNorm35619mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=35619
NCI ThesaurusC61926ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61926
FDA Substance Registration SystemL36O5T016Nprecision.fda.gov/uniisearch/srs/unii/L36O5T016N

DailyMed Socrata Ingredients#

Type, DailyMed label, SPL version table
TypeDailyMed labelSPL version
ACTIVE MOIETYThese highlights do not include all the information needed to use XIFAXAN safely and effectively. See full prescribing information for XIFAXAN. XIFAXAN® (rifaximin) Tablets Initial U.S. Approval: 2004 To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.1
ACTIVE INGREDIENTThese highlights do not include all the information needed to use XIFAXAN safely and effectively. See full prescribing information for XIFAXAN. XIFAXAN® (rifaximin) Tablets Initial U.S. Approval: 2004 To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.1
ACTIVE MOIETYThese highlights do not include all the information needed to use XIFAXAN safely and effectively. See full prescribing information for XIFAXAN. XIFAXAN® (rifaximin) Tablets Initial U.S. Approval: 2004 To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.2
ACTIVE INGREDIENTThese highlights do not include all the information needed to use XIFAXAN safely and effectively. See full prescribing information for XIFAXAN. XIFAXAN® (rifaximin) Tablets Initial U.S. Approval: 2004 To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.2
ACTIVE INGREDIENTXIFAXAN (RIFAXIMIN) TABLET [SALIX PHARMACEUTICALS, INC.]23
ACTIVE MOIETYXIFAXAN (RIFAXIMIN) TABLET [SALIX PHARMACEUTICALS, INC.]23
ACTIVE INGREDIENTXIFAXAN (RIFAXIMIN) TABLET [CARILION MATERIALS MANAGEMENT]2
ACTIVE MOIETYXIFAXAN (RIFAXIMIN) TABLET [CARILION MATERIALS MANAGEMENT]2